Can Fluoxetine and Mirtazapine Be Taken Together?
Yes, fluoxetine and mirtazapine can be taken together, and this combination is supported by clinical evidence showing enhanced efficacy compared to monotherapy, with acceptable tolerability. 1
Evidence for Combination Therapy
The combination of fluoxetine and mirtazapine has been specifically studied in a double-blind randomized trial that demonstrated:
- Remission rates of 52% with mirtazapine plus fluoxetine versus only 25% with fluoxetine monotherapy after 6 weeks 1
- The combination was as well tolerated as fluoxetine alone despite theoretical concerns about drug interactions 1
- This approach aligns with broader evidence showing that switching or augmenting with mirtazapine produces similar efficacy to other second-step strategies 2
Pharmacokinetic Considerations
While fluoxetine is a CYP2D6 inhibitor and mirtazapine is partially metabolized by this enzyme, the clinical significance appears limited:
- Studies with paroxetine (another SSRI and CYP2D6 inhibitor) showed only modest increases in mirtazapine levels (17% increase in AUC) without requiring dose adjustments 3
- No dose adjustment of either drug is necessary when combining mirtazapine with SSRIs 3
- More recent pharmacokinetic modeling confirms that while fluoxetine affects mirtazapine clearance, the effect is manageable in clinical practice 4
Critical Safety Monitoring
Serotonin syndrome risk is the primary concern when combining these medications. The FDA label for mirtazapine explicitly warns about this potentially life-threatening condition when combined with SSRIs 5. Monitor for:
- Agitation, confusion, tachycardia
- Tremors, muscle rigidity, myoclonus
- Hyperthermia, diaphoresis
- Nausea, vomiting, diarrhea
If serotonin syndrome symptoms develop, immediately discontinue both medications and seek emergency care 5.
Additional Monitoring Requirements
Watch for these mirtazapine-specific risks that may be relevant regardless of combination:
- Agranulocytosis: Monitor for fever, sore throat, or signs of infection, particularly in the first 2 months 5
- QTc prolongation: Exercise caution if the patient has cardiovascular disease or takes other QTc-prolonging medications 5
- Weight gain and increased appetite: Occurs in 49% of patients in some studies 5
Clinical Bottom Line
The combination is evidence-based for treatment-resistant depression, with double the remission rate compared to monotherapy 1. The theoretical pharmacokinetic interaction is clinically insignificant 3, but vigilance for serotonin syndrome is mandatory given the FDA warning about combining mirtazapine with SSRIs 5. Start with standard doses (fluoxetine 20 mg, mirtazapine 30 mg) without adjustment 1, 3, and educate patients about serotonin syndrome symptoms requiring immediate medical attention.